The pharmacokinetics of escitalopram in patients with hepatic impairment
- 1 March 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in The AAPS Journal
- Vol. 8 (1), E14-E19
- https://doi.org/10.1208/aapsj080102
Abstract
The effect of hepatic impairment on the pharmacokinetics of escitalopram was determined by means of nonlinear mixed effect modeling, considering both the Child-Pugh classification (and its components) and cytochrome P450 2C19 (CYP2C19) activity. Twenty-four subjects were grouped according to their Child-Pugh score as healthy, with mild hepatic impairment or with moderate hepatic impairment. The subjects were administered a single oral dose of escitalopram 20 mg, and blood was sampled up to 168 hours after dosage. The serum concentration of escitalopram was determined and the pharmacokinetics assessed by nonlinear mixed effect modeling. The CYP2C19 activity was measured from the urinary excretion ratio of S/R-mephenytoin. All subjects tolerated the treatment well, and no serious adverse events were reported. Predicted mean area under the curve from zero to infinity (AUCinf) values were 51% and 69% higher for patients with mild and moderate hepatic impairment (Child-Pugh classification), respectively, compared with healthy subjects. The best-fitting model showed an influence of CYP2C19 activity on clearance and body weight on the volume of distribution for escitalopram. CYP2C19 activity is a better predictor of escitalopram clearance than is Child-Pugh classification.Keywords
This publication has 10 references indexed in Scilit:
- Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram.2001
- Selective effect of liver disease on the activities of specific metabolizing enzymes: Investigation of cytochromes P450 2C19 and 2D6*Clinical Pharmacology & Therapeutics, 1998
- Stereoselective Biotransformation of the Selective Serotonin Reuptake Inhibitor Citalopram and Its Demethylated Metabolites by Monoamine Oxidases in Human LiverBiochemical Pharmacology, 1998
- Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects.European Journal of Clinical Pharmacology, 1998
- Clinical Pharmacokinetic and Pharmacodynamic Considerations in Patients with Liver DiseaseClinical Pharmacokinetics, 1995
- Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatmentJournal of Hepatology, 1995
- Effect of liver disease on dextromethorphan oxidation capacity and phenotype: a study in 107 patients.British Journal of Clinical Pharmacology, 1989
- Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphismClinical Pharmacology & Therapeutics, 1984
- Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in manEuropean Journal of Clinical Pharmacology, 1984
- Transection of the oesophagus for bleeding oesophageal varicesBritish Journal of Surgery, 1973